Drug Regulatory Authority Pakistan (DRAP) has given their first ever approval of a new molecule on indigenous data. Cansino Bio COVID 19 Vaccine has been approved in Feb 2021 for EUA by DRAP after evaluation of interim analysis of >17000 Pakistani subject.

Dimension Research has the honor to provide site regulatory, management and monitoring services in this land mark Phase III study in Pakistan history; sponsored by CanSino Biologics on China in collaboration with NIH, Pakistan.

This Phase III study by CanSino Biologics has been conducted in 70 sites in 05 countries involving about 40,000+ volunteers. The aim of study was to observe the efficacy and safety of their vaccine.

CanSino Biologics Inc.’s experimental coronavirus shot has an average efficacy rate of 65.7% at preventing symptomatic cases and in Pakistan efficacy at preventing symptomatic cases is 74.8% and 100% at preventing sever disease, making it the latest vaccine candidate to show some protection against Covid-19

Dimension Research has managed this study at 05 sites i.e., Aga Khan University Hospital-Karachi, Indus Hospital-Karachi, University of Health & Sciences-Lahore, Shaukat Khanum Memorial Hospital-Lahore and Shifa International Hospital-Islamabad. The enrolment was completed within 04 months and follow up will be completed by early 2022.

Dimension Research efforts has been commended by the Country PI Maj Gen Aamir Ikram, the NIH team members, CanSino Bio and all the sites PIs, site study coordinators and central lab personnel in Canada. Our highly trained and dedicated team will be working with the sites till the study data lock.